Trikafta benefits varied by genotype, prior treatment, and baseline lung function Written by Andrea Lobo, PhD Trikafta (elexacaftor/tezacaftor/ivacaftor) was associated with improved lung function and fewer pulmonary exacerbations, or sudden worsening of lung symptoms, in children ages 6 to 11 with cystic fibrosis (CF), a real-world study found. The treatment was also associated with improved nutritional status, fewer hospitalizations and antibiotic treatments, and reduced us

Many have questions about fertility, pregnancy, CF treatment effects Written by Patricia Inácio, PhD Most adults with cystic fibrosis (CF) surveyed at a U.S. care center had never received genetic counseling, and many had unanswered questions about fertility, pregnancy, and family planning. Among more than 100 respondents, 71% had not received genetic counseling, and 27% had never heard of it. Fifty-four percent of those who had not received counseling said they thought it wo

CFF-funded ICFTN training, MECFA MADI diagnostic donations, European CF registry participation, and Vertex free modulator access converge to bring comprehensive CF support to Pakistani patients for the first time. KARACHI / ISTANBUL / BOSTON — The Middle East Cystic Fibrosis Association (MECFA) and the Marmara University Cystic Fibrosis Center have completed a clinical assessment visit to the Indus Hospital and Health Network (IHHN) in Karachi, launching a structured CF capac